Episurf — Regulatory Filings 2021

Sep 29, 2021

New Chinese patent approval for Episurf Medical

Episurf Medical (NASDAQ: EPIS B) has received another Notice of Allowance from the Chinese patent office SIPO. The patent, entitled "Method and node for manufacturing a surgical kit for cartilage repair", covers a medical image segmentation process for 3D visualisation of anatomical joints.

"Image segmentation is a crucial part of the technology around Episurf Medical's individualised joint implants and surgical instruments. This is a comprehensive patent in the field of 3D visualisation of joints with a broader scope than the company's related patents", comments Katarina Flodström, COO, Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be costefficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10:30 CEST on 29 September 2021.